Analytic bias among certified methods for the measurement of hemoglobin A1c: A cause for concern?

American Journal of Clinical Pathology

Volumn 129, Issue 4, 2008, Pages 540-547

  Holmes, Earle W ^a,b   Erşahin, Çaǧatay ^a   Augustine, Geri J ^a   Charnogursky, Gerald A ^a   Gryzbac, Margie ^a   Murrell, Joanne V ^a   McKenna, Kathleen M ^a   Nabhan, Fadi ^a   Kahn, Stephen E ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Analytic error; Diabetes; Hemoglobin A1c; Point of care testing

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; LABORATORY TEST; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; TIME SERIES ANALYSIS; BLOOD ANALYSIS; COMPARATIVE STUDY; EPIDEMIOLOGY; HOSPITAL INFORMATION SYSTEM; LABORATORY; PREDICTION AND FORECASTING; QUALITY CONTROL; REPRODUCIBILITY; STANDARD; STATISTICS;

BIAS (EPIDEMIOLOGY); BLOOD CHEMICAL ANALYSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LABORATORIES; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS;

EID: 42949149265     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/U3GPPTCBP1VLL8AW     Document Type: Article

References (29)

1. 1c standardisation destination: global IFCC standardisation: how, why, where and when: a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clin Biochem Rev. 2005;26:5-19.
2. Little RR. Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med. 2003;41:1191-1198.
3. National Glycohemoglobin Standardization Program. NGSP site index. http://www.ngsp.org/prog/index.html. Accessed August 9, 2007.
4. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care. 2004;27(suppl 1):S91-S93.
5. Little RR, Rohlfing CL, Wiedmeyer HM, et al. The National Glycohemoglobin Standardization Program: a five-year progress report. Clin Chem. 2001;47:1985-1992.
6. 1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem. 2005;51:753-758.
7. 1c. August 30, 2005. http://www.cms.hhs. gov/determinationprocess/downloads/id35TA.pdf. Accessed August 9, 2007.
8. 1c testing for evaluation of glucose control. California Technology Assessment Forum. October 8, 2003. http://www.ctaf.org/content/general/ detail/566. Accessed Aug 9, 2007.
9. Aarsand AK, Alter D, Frost SJ, et al. Diagnosis and management of diabetes mellitus. In: Nichols JH, ed. Evidence-Based Practice for Point-of-Care Testing. Washington, DC: AACC Press; 2007.
10. American Diabetes Association. Standards of medical care in diabetes: 2006 [published correction appears in Diabetes Care. 2006;29:1192]. Diabetes Care. 2006;29(suppl 1):S4-S42.
11. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13:4-68.
12. AQA Alliance. AQA approved quality measures. June 2007. http://www.aqaalliance.org/files/ ApprovedPerformanceMeasures.xls. Accessed August 9, 2007.
13. 1c measurement. 2002. http://www. pasa.doh.gov.uk/ evaluation/docs/pathology/MDA_03016. pdf. Accessed August 7, 2007.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
15. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
16. Moridani MY, Verjee Z, Allen LC. Analytical evaluation of hemoglobin A(1c) dual kit assay on Bio-Rad Variant II: an automated HPLC hemoglobin analyzer for the management of diabetic patients. Clin Biochem. 2003;36:317-320.
17. Higgins TN, Blakney GB, Dayton J. Analytical evaluation of the Bio-Rad Variant II automated HbA(1c) analyzer. Clin Biochem. 2001;34:361-365.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
19. Fraser CG, Kallner A, Kenny D, et al. Introduction: strategies to set global quality specifications in laboratory medicine. Scand J Clin Lab Invest. 1999;59:477-478.
20. 1c. Scand J Clin Lab Invest. 2002;62:609-622.
21. Ricós C, Garcia-Lario J-V, Alvarez V, et al. Biological variation database, and quality specifications for imprecision, bias and total error: the 2006 update. http://www.westgard.com/ guest32.htm. Accessed August 9, 2007.
22. Shephard MDS. Analytical goals for point-of-care testing used for diabetes management in Australian health care settings outside the laboratory. Point of Care. 2006;5:177-185.
23. White GH, Farrance I. Uncertainty of measurement in quantitative medical testing: a laboratory implementation guide. Clin Biochem Rev. 2004;25(suppl):S1-S23.
24. Westgard JO, Darcy T. The truth about quality: medical usefulness and analytical reliability of laboratory tests. Clin Chim Acta. 2004;346:3-11.
25. US Department of Health and Human Services. Medicare MaCp. Laboratory requirements related to quality systems and personnel qualifications. Final rule. Fed Regist. 2003;68:3640-3714.
26. 1c. Clin Chem. 2005;51:681-683.
27. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278.
28. Leichter SB. Pay-for-performance contracts in diabetes care. Clinical Diabetes. 2006;24:56-59.
29. 1c goals in diabetes care: pass/fail or partial credit. JAMA. 2007;297:520-523.